Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) on April 28 and set a price target of $5.00.
Jason McCarthy’s rating is based on the promising preclinical data presented by Actinium Pharmaceuticals for their therapies, Actimab-A and ATNM-400. Actimab-A showed strong antileukemic effects in acute myeloid leukemia (AML) models, demonstrating its mutation-agnostic potential when combined with standard AML therapies, which could lead to significant advancements in AML treatment. Furthermore, the preclinical results indicated enhanced tumor growth suppression and improved survival outcomes, which are encouraging signs for its upcoming pivotal study.
Additionally, ATNM-400 exhibited superior tumor growth inhibition in prostate cancer models compared to existing treatments, highlighting its potential as an alternative therapy. The positive data, combined with the company’s strong financial position, with $72.9 million in cash providing a runway into the second half of 2026, supports the Buy rating. The valuation model anticipates commercialization of Actimab-A in 2027 and Iomab-B in 2028, with risk adjustments applied to account for clinical and regulatory uncertainties, leading to a 12-month price target of $5.00.
According to TipRanks, McCarthy is an analyst with an average return of -24.0% and a 23.64% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Medicus Pharma Ltd, and SELLAS Life Sciences Group.
In another report released on April 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.